By Nina Sparano. jerod hagen, 43 naples, FL. A commanding on-air presence. Evening news anchor at “Patients who had a higher RS and a higher clinical risk within this younger group seemed to derive benefit,” explained Sparano.At 9 years, in those with a RS of 16-20, a 1.6% absolute benefit from chemotherapy was observed versus a 6.5% absolute benefit in those with RS ranging from 21 to 25, added Sparano.An exploratory analysis looking at the impact of age and menopausal status on chemotherapy benefit in patients with a RS ranging from 16 to 25 showed that there was no benefit in older women with an increasing score. By Nina Sparano. Along the way, Nina has taken home multiple awards for spot news, specialty reporting, and anchoring. Nina says she feels honored to be welcomed back into television news community and has finally found her home here at NBC26 and northeastern Wisconsin. When she’s not on the anchor desk, Nina loves to cook, spend time with her husband and two young girls, fishing, taking her kids to the local library, hanging out with friends and squeezing in a boot-camp class at the YMCA whenever possible. In 2014 Nina took a step back from news to raise her two young children and along the way moved her family to Northern Colorado, Louisiana and now Wisconsin. She began her career as a morning anchor at KPAX-TV in Nina also spent 5 years in Denver, Colorado as a reporter and fill-in anchor at KDVR- Fox31 Denver and later at KCNC- CBS Denver.Throughout her years in the business, Nina has covered some of the nation’s most gripping stories from school and church shootings to wildfires and the 1,000-year flood that devastated much of northern, central and southern Colorado. Known Locations: Appleton WI, 54913, Lafayette LA 70508, Oshkosh WI 54904 Possible Relatives: Jared Patrick Bartels, Julie R Bartels, Terry P Bartels. Nina Sparano is an Anchor on NBC26. Nina Sparano Show Filters Nina Sparano. “Interestingly, younger women really had no benefit, suggesting that some of the effect that was seen with chemotherapy in these younger patients who had higher RS might have been due to a castration effect,” explained Sparano.At 9 years, a 3% distant recurrence with endocrine therapy alone was observed in patients with an RS of 0 to 10 (arm A). 2 Nina Sparano stock pictures and images Browse 2 nina sparano stock photos and images available, or start a new search to explore more stock photos and images. Patients who had discordance in their clinical and genomic risks were randomized to receive either no chemotherapy or chemotherapy.“No effect with chemotherapy was observed in older women, but there was a 5% benefit from chemotherapy in younger women, which is very similar to what we saw in TAILORx,” said Sparano.The phase 3 Plan B trial used the Oncotype DX Recurrence Score to define a genomically low-risk subset of patients with clinically high-risk pN0-1 early breast cancer for adjuvant treatment with endocrine therapy alone.
However, curves began to separate for younger women with a RS of less than 25, noted Sparano.When examining absolute differences in 9-year distant recurrence rates by chemotherapy use in women 50 years or younger with RS of 16 to 25 stratified by RS and clinical risk, investigators noted that the estimated absolute benefit of chemotherapy in women with a RS of 16 to 20 who were not stratified by clinical risk was +1.6%. This material may not be published, broadcast, rewritten, or redistributed. Find the best way to get in touch with Nina by joining Muck Rack.
Specialising in long form and technology reporting. Throughout her years in the business Nina has covered some of the nation’s most gripping stories from school and church shootings to wildfires and the one-thousand year flood that devastated much of northern, central and southern Colorado.
In those with a RS between 26 and 100 (Arm D), a 13% distant recurrence was observed, despite chemotherapy plus endocrine treatment.The MINDACT trial included 6,693 patients who were assigned to a clinical risk or a genomic risk.
6:00, 6:30 & 10:00 pm Anchor at NBC 26 in Green Bay, WI richard palys, 41 naples, FL. A total of 3198 patients were enrolled on the trial and chemotherapy was omitted in 86.1% of eligible patients with a RS of 11 or less.At a median follow-up of 5 years, DFS in the patients treated with endocrine therapy alone who had a RS of 11 of less was 94% versus 94% in those with an RS between 12 and 25 and 84% in those with an RS of greater than 25 (“This provided a limited amount of level 1 evidence supporting the use of the Oncotype assay in patients with low-volume disease,” noted Sparano.With all of the data yielded thus far, it is clear that gene expression assays provide prognostic information, that the 21-gene assay offers predictive information, and that the 70-gene assay provides prognostic information, according to Sparano.“It’s important to remember that these assays are not interchangeable, and there’s a lack of concordance in risk classification which needs to be considered when deciding which assay to use and what to do with the information yielded,” concluded Sparano.